Post-COVID-19 Advancing Targeted Drug Delivery (TDD): Literature Insights and Market Dynamics

This chapter investigates the evolving role of targeted drug delivery (TDD) in the biotech and pharmaceutical industries, emphasizing the importance of predictive accuracy and interdisciplinary collaboration in optimizing drug delivery systems (DDSs). We explore various nanocarriers, including liposomes and dendrimers, and their structural features, highlighting their interactions within physiological barriers, such as the blood-brain barrier (BBB). Emphasizing the multifaceted applications of nanotechnology in TDD, we also address scalability challenges that arise when transitioning from lab-scale research to industrialscale production. The COVID-19 pandemic accelerated the need for innovative DDSs, and our discussion underscores the importance of collaborative partnerships and regulatory compliance. We leverage the Analytic Hierarchy Process (AHP) to evaluate socioeconomic factors affecting TDD market expansion, highlighting the integration of predictive models with experimental data. Moreover, Eroom’s Law is considered within the context of declining pharmaceutical R&D efficiency, arguing that TDD’s advancements in personalized medicine and precision drug targeting are key to overcoming these inefficiencies. This paper concludes by reflecting on ethical considerations in in-vivo and in-vitro evaluations